Investment Rating - The report maintains a "Buy" rating for CATL A/H shares with a 12-month price target of Rmb 323.00 for A-shares and HK$ 411.00 for H-shares, indicating an upside of 19.3% and 6.8% respectively [8][15]. Core Insights - The report highlights three key focuses for CATL: unit gross profit (GP) expansion, upward trend in capital expenditures (CAPEX), and progress in the US market which may enhance the total addressable market (TAM) [15][16]. Summary by Sections Earnings Preview - CATL is expected to report revenue of Rmb 104.7 billion and net profit of Rmb 15.6 billion in 2Q25, with unit GP anticipated to increase to Rmb 150/kWh from Rmb 147/kWh in 1Q25, driven by strong overseas shipments [1][41]. Unit GP Expansion - The blended battery unit GP is projected to expand due to improved product mix, with overseas EV sales in Europe showing a 28% year-over-year growth in the first five months of 2025 [1][19]. CATL is estimated to account for about 70% of Europe's battery imports from China [1][20]. CAPEX Trends - The report revises up CAPEX forecasts for 2025-2027 by 25%-5%, expecting CATL's relative CAPEX share to rise from approximately 13% in 2024 to around 24% in 2025, which is expected to drive market share gains [16][30]. US Market Progress - Recent developments regarding Ford's Michigan LFP battery factory, which utilizes CATL's technology, suggest improved market access for CATL in the US, potentially increasing its TAM [16][19]. Financial Projections - Revenue projections for CATL are set at Rmb 362 billion for 2024, Rmb 436 billion for 2025, and Rmb 532 billion for 2026, with EBITDA expected to grow significantly over the same period [3][13]. EPS is forecasted to increase from Rmb 11.58 in 2024 to Rmb 22.45 by 2027 [3][13]. Market Position - CATL's market capitalization is noted at Rmb 1.2 trillion, with a strong enterprise value of Rmb 972.5 billion, indicating robust financial health and market positioning within the battery industry [3][5].

Investment Rating - The report does not explicitly provide an investment rating for Time Interconnect (1729.HK) Core Insights - Time Interconnect is expected to experience revenue growth in 2025 driven by rising AI demand, production site diversification, and exposure to various end markets [1][8] - The company reported revenues of HK$7.4 billion in 2024, with a gross margin of 14.6% [3] - The revenue from server ODM business reached HK$3.2 billion in 2024, accounting for 43% of total revenue [7] Summary by Sections Industry Overview - Time Interconnect specializes in customized copper and optical fiber cables, as well as servers ODM, with production sites in mainland China, Japan, and Mexico [3] - Key applications include telecommunications, data centers, industrial equipment, medical equipment, and automotive wiring harnesses [3] Growth Drivers - AI demand is driving the adoption of high-speed cables, with a reported 208% year-over-year growth in high-speed cable revenues in 2024 [4] - 42% of cable assembly revenues were derived from data center clients in 2024, indicating strong demand from this sector [4] Business Outlook - Management is optimistic about revenue growth in 2025, supported by the expansion of the Mexican production site and increasing capex spending from Chinese CSP clients [8] - The planned acquisition of Leoni AG is expected to diversify the business into automotive cables and wiring harnesses [8]

Investment Rating - The report maintains a Neutral rating for Hua Hong, with a 12-month target price of HK$40.9, indicating a relatively lower upside potential from the current price of HK$35.65, which translates to an upside of 14.7% [1][12]. Core Insights - Hua Hong's management is optimistic about operations, reporting that utilization (UT) rates across major fabs are at 100% or above, driven by strong demand in power discrete, microcontrollers (MCUs), and power management integrated circuits (PMICs) [1][3]. - The company has begun to implement price increases for both 8-inch and 12-inch products, anticipating that this will enhance gross margins in the upcoming quarters [2][11]. - Capacity expansion is ongoing, with plans to ramp up the second 12-inch fab to 83,000 wafers per month (wpm) and potential future capacities at 28nm and 22nm [4][11]. Pricing Outlook - The pricing strategy is set to improve, with management confident in the ability to raise prices due to solid demand, which is expected to positively impact gross margins [2][11]. Utilization Rates - Management reports full loading across its fabs, except for the new fab that is in the ramp-up phase, with a noted recovery in demand for power discrete products and sustained demand for PMICs related to AI applications [3][11]. Capacity Expansion Plans - The second 12-inch fab is being ramped up, with expectations to achieve positive gross margins once it surpasses 50,000 wpm of loading, while the first 12-inch fab is already achieving positive gross margins [4][8]. Financial Projections - Revenue projections for the next few years indicate growth, with expected revenues of $2,004 million in 2024, increasing to $3,910.5 million by 2027 [12].

Investment Ratings - PetroChina: Buy with a 12-month target price of HK$8.30/Rmb12.60, reflecting a potential upside of 21.5% [19][24] - CNOOC: Buy with a 12-month target price of HK$20.90, indicating a potential upside of 14.6% [26][29] - Sinopec: Neutral with a 12-month target price of HK$3.70/Rmb4.90, suggesting a downside of 11.7% [30][35] Core Insights - The report emphasizes a preference for free cash flow (FCF) leaders like PetroChina and CNOOC, both expected to achieve double-digit FCF yields in 2026E [2][19] - PetroChina and CNOOC are projected to achieve FCF breakeven at Brent oil prices of US$30-$40/bbl, with attractive FCF yields of approximately 11% for both companies under various oil price scenarios [21][17] - Sinopec is expected to face weak FCF due to prolonged chemical market surplus and elevated capital expenditures, leading to a Neutral rating [30][39] Summary by Sections Earnings Estimates - PetroChina's estimated net income for 2Q is projected to decline by 30% year-on-year, while Sinopec's is expected to drop by 46% [1] - CNOOC's 1H net income is estimated to decrease by 16% year-on-year [1] Valuation Comparisons - PetroChina and CNOOC are trading at discounted valuations of 3.1X-3.2X on 2026 EV/DACF compared to a global average of 5.5X [2][14] - The report highlights that both companies could maintain attractive FCF yields even at lower oil prices, with PetroChina and CNOOC achieving yields of approximately 10% and 9% respectively at US$60/bbl [2][18] Price Sensitivity Analysis - For PetroChina, total EBITDA is projected to range from Rmb351.6 million at US$50/bbl to Rmb542.5 million at US$90/bbl [20] - CNOOC's EBITDA is expected to range from Rmb176.2 million at US$50/bbl to Rmb308.0 million at US$90/bbl [28] Market Dynamics - Recent geopolitical events have supported oil prices, leading to low domestic oil product inventories and robust refining margins despite weak demand [1][2] - The report notes that deep utilization cuts among state-owned refiners have contributed to the current market conditions [2][8]

Investment Rating - The report does not explicitly provide an investment rating for Lens Tech (300433.SZ) as it is categorized as "Not Covered" [1]. Core Insights - Management is optimistic about the demand for foldable phones, driven by differentiation, new use cases, and improved technology that enhances user experience [1][4]. - The company is diversifying its end markets beyond smartphones to include vehicle glass, AI glasses, and robotics, which supports long-term growth [1][8]. Summary by Sections Foldable Phones - Foldable phones are expected to drive significant growth, with management highlighting strong market demand and potential for increased shipments [4][7]. - The global shipment penetration rate for foldable phones is projected to rise from 1.5% in 2024 to 4.1% by 2027, excluding iPhones [2]. Vehicle Glass Expansion - Lens Tech is expanding into vehicle glasses, leveraging its experience in smartphone glass to provide high-precision and lighter-weight solutions for leading car OEMs [8]. - The company is collaborating with over 30 electric vehicle manufacturers, indicating a strategic move into the automotive sector [9]. Long-Term Outlook - Revenue growth in 2025 is anticipated to be bolstered by new smartphone model launches and the increasing trend of foldable phones [9]. - Contributions from vehicle glasses and AI/AR glasses are expected to ramp up over the long term, driven by rising popularity and affordability [9].

30% 40% 50% Jan-23 Apr-23 Jul-23 Oct-23 Jan-24 Apr-24 Jul-24 Oct-24 Jan-25 Apr-25 SNE data Battery Alliance data 41.8% 42.1% CATL's domestic ePV battery market share Source: SNE, CPCA, Battery Alliance, Morgan Stanley Research Morgan Stanley Asia Limited+ Jack Lu Equity Analyst Jack.Lu@morganstanley.com +852 2848-5044 July 4, 2025 06:19 AM GMT M Update Contemporary Amperex Technology Co. Ltd. | Asia Pacific CATL Losing Share in China? Not Really Key Takeaways Exhibit 1: Battery Alliance data shows that CATL ...

Investment Rating - The report does not provide a specific investment rating for Conant Optical (2276.HK) as it is categorized as "Not Covered" [1]. Core Insights - Conant Optical is expanding its business from traditional spectacle lenses to AI/AR glasses, anticipating sustained growth in its core business and increased demand for AI/AR glasses due to their higher dollar content and specific client requirements [1][2]. - The company is positioned to benefit from the growing AI/AR glasses market, with expectations of a 56% CAGR in shipments in China from 2024 to 2030, reaching 7 million units by 2030 [2]. - Conant's customized lenses for AI/AR glasses are designed to be lighter and thinner, with a significant increase in average selling price (ASP) compared to traditional lenses [4]. Summary by Sections Company Profile - Conant Optical is a leading resin lenses manufacturer in China, with 44% of its revenues from standardized lenses, 37% from functional lenses, and 19% from customized lenses, which have a higher gross margin [3]. - The company operates in 90 countries and ranks among the top 10 resin lenses manufacturers globally by revenue [3]. Market Outlook - Management expresses optimism about the AI/AR glasses market's growth potential, indicating that Conant will be a key beneficiary due to its customized lens solutions for both global and local clients [8]. - The company plans to enhance its market presence by partnering with offline stores in China to facilitate the lens ordering process for consumers [8]. Production Capabilities - Conant has demonstrated strong mass production capabilities, allowing it to produce millions of customized lenses quickly, supported by its precision manufacturing skills [7]. - The company is expanding its production capacity with a new plant in Thailand expected to commence operations in 2026 [7].

Investment Rating - The investment rating for China Resources Pharmaceuticals is Neutral with a 12-month price target of HK$6.17, representing an upside potential of 18.8% from the current price of HK$5.19 [8][29]. Core Insights - The company is experiencing soft growth in the first half of the year, leading management to lower previous guidance of double-digit year-on-year sales growth for 2025, pending a recovery in the second half [1][2]. - The distribution business is facing challenges due to a tough industry environment, and there are no clear signals of growth recovery as the national medical reimbursement fund remains tight [2][3]. - Cash collection is under pressure, with hospitals' financial positions still strained, resulting in delayed payments for non-VBP products despite some acceleration in cash collection for VBP products [3]. Summary by Sections Financial Performance - Revenue for 2025 is projected to be HK$271.5 billion, with a 5-year EPS CAGR of 10% for the manufacturing business and 5% for the distribution business [7]. - The company’s market cap is HK$32.6 billion, with an enterprise value of HK$133.8 billion [8]. Business Segments - The manufacturing business is valued at HK$31.4 billion, while the distribution business is valued at HK$4.1 billion [7]. - Specific challenges include slower growth for Sanjiu due to a high base, pressure on Boya from albumin VBP, and a softer growth trajectory for plasma collection [2]. Cash Management - To alleviate cash pressure, the company is managing its cash cycle actively, including de-prioritizing high-risk regions for receivables [3].

Investment Rating - The report maintains a "Buy" rating for both JD Health and Meituan, indicating a positive outlook for their stock performance in the healthcare sector [5][22]. Core Insights - The pharmaceutical retail O2O market in China is characterized by strong competition, with Meituan being the largest player due to its delivery capabilities and early market entry in 2013. JD Health is emerging as a significant competitor with advantages in supply chain and asset-heavy business model [2][4]. - Meituan's healthcare product GMV is estimated to reach approximately Rmb45 billion in 2023, with a target growth rate of at least 30% annually. The majority of its healthcare-related GMV comes from O2O sales [2][3]. - JD Health's asset-heavy model may provide a competitive edge in the healthcare industry, as many services require offline provision and have higher logistics demands. JD Health's scale gives it stronger bargaining power with suppliers [4][5]. Summary by Sections Meituan's Position - Meituan has captured a significant share of the pharmacy market, with around 250,000 pharmacies operating on its platform. The company aims to expand its healthcare segment despite challenges in driving growth due to market saturation [2][3]. - The expert suggests potential strategies for Meituan to enhance growth, including integration with the medical beauty segment and lobbying for reimbursement of O2O drug orders in more cities [3]. JD Health's Competitive Edge - JD Health operates its own offline pharmacies, which provides it with a supply chain advantage over Meituan. This model may be more suitable for the healthcare sector, where offline services are crucial [4]. - The report highlights that JD Health could outperform revenue growth expectations due to strong drug sales and gross profit margin expansion [5]. Market Outlook - The internet healthcare space is viewed positively due to its high growth visibility and potential catalysts such as AI and consumption recovery. Both JD Health and Meituan are expected to benefit from these trends [5].

Investment Rating - The investment rating for the report is "Overweight" [3][16]. Core Insights - The report highlights the technology and leadership position of Contemporary Amperex Technology Co. Ltd (CATL) in the global electric vehicle (EV) and energy storage system (ESS) battery markets, emphasizing its ability to maintain resilient profits despite pricing pressures in the supply chain [11][16]. - The price target for CATL is set at Rmb370.00 for June 2026, based on a projected P/E ratio of 20x for 2026E-27E, which is at the lower end of the company's historical trading range due to slower industry growth compared to earlier stages [12][17]. Financial Estimates - For FY25E, net sales are projected at Rmb404,942 million with a year-over-year growth of 12% [5]. - The gross profit for FY25E is estimated at Rmb99,220 million, maintaining a gross margin of 25% [5]. - The adjusted net income for FY25E is forecasted to be Rmb61,861 million, reflecting a net profit growth of 22% year-over-year [5][20]. Performance Drivers - The report identifies various performance drivers, including market factors contributing 27%, regional factors at 23%, and macroeconomic factors at 13% [13]. - The correlation of CATL's performance with the MSCI Asia Pacific ex-Japan index is noted at 0.62 over six months and 0.53 over one year [13]. Valuation Metrics - The report provides valuation metrics, indicating an expected revenue growth of 19.7% for FY26E and an EBITDA margin of 25.5% for the same year [14]. - The adjusted P/E ratio is projected to decrease from 21.8 in FY24A to 12.4 in FY27E, reflecting a more favorable valuation over time [14][20].